The RETRAIN Trial (Phase 1)

Countess of Chester NHS Foundation Trust18 enrolled

Overview

The primary objective is to investigate in stroke patients the impact of geko™ NMES treatment, when used as standard of care for VTE prevention, on brain haemodynamics at different stimulation levels and in three different postural positions (supine, semi-supine \[45° seated\] and seated). The aim is to identify the optimal stimulation level and postural position for the maximum response (NMES versus no NMES) with regard to relative total haemoglobin concentration (i.e., the sum of relative deoxyhaemoglobin and oxyhaemoglobin concentrations) using fNIRS and EEG.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Ischaemic Stroke

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult over 18 * Patient with ischaemic stroke diagnosis confirmed by a stroke physician. * No intracerebral haemorrhage as ruled out by computerised tomography (CT) or MRI scan. * Able to achieve a supine, sitting and semi-sitting position of 45° with the help of another person. * Receiving geko™ NMES treatment as standard of care for VTE prevention Exclusion Criteria: * Inability to gain consent from the patient. * A transient ischaemic attack (TIA). * Stroke survivors with ischaemic stroke less than 7 days from onset. * History of epilepsy. * Below/above knee amputation. * History of established peripheral neuropathy. * Too unwell to participate as judged by physician. * Use of any other neuromodulation device that may interact with NMES

Locations (2)

Countess of Chester Hospital NHS Foundation Trust

Chester, Cheshire, United Kingdom

Countess of Chester Hospital NHS Foundation Trust

Chester, Cheshire, United Kingdom

Outcomes

Primary Outcomes

Primary outcome

a change in brain haemodynamics (or blood flow) in terms of oxygenated and de-oxygentated blood from baseline to end of study participation.

Time frame: 3 hours

Secondary Outcomes

Secondary objective

Neurovascular coupling, Cerebral autoregulation and dynamic functional connectivity

Time frame: 3 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.